Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.88 |
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.88 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430797 | 1.00 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1PDE4APDE4BPDE4C | |
| SCHEMBL2430152 | 0.94 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1 | |
| SCHEMBL2430156 | 0.94 | HSP90AA1 (0.89) | HSP90AA1HSP90AB1 | |
| SCHEMBL2425426 | 0.94 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1 | |
| SCHEMBL2425424 | 0.94 | HSP90AA1 (0.88) | HSP90AA1HSP90AB1 | |
| SCHEMBL2429433 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL2429436 | 0.94 | HSP90AA1 (1.00) | HSP90AA1HSP90AB1 | |
| SCHEMBL2428160 | 0.93 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1 | |
| SCHEMBL2428162 | 0.93 | HSP90AA1 (0.87) | HSP90AA1HSP90AB1 | |
| SCHEMBL2427717 | 0.93 | HSP90AA1 (0.84) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2074120-B1 | TROPANE COMPOUNDS | EXELIXIS INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-2074120-A1 | TROPANE COMPOUNDS | Exelixis, Inc. (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163471-A1 | Tropane compounds | EXELIXIS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163471-A1 | Tropane compounds | ADRA1B, ADRA2B, ADRB2 | HSP90AA1 1888/4885HSP90AB1 1352/4885PDE4A 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.